- Language: English
- Published: August 2012
Raptor Pharmaceuticals Corp. - Product Pipeline Review - H2 2011
- ID: 1943815
- October 2011
- 101 pages
- Global Markets Direct
Raptor Pharmaceuticals Corp. – Product Pipeline Review – H2 2011
Global Market Direct’s pharmaceuticals report, “Raptor Pharmaceuticals Corp. - Product Pipeline Review - H2 2011” provides data on the Raptor Pharmaceuticals Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Raptor Pharmaceuticals Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Raptor Pharmaceuticals Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Raptor Pharmaceuticals Corp. - Brief Raptor Pharmaceuticals Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Raptor Pharmaceuticals Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Raptor Pharmaceuticals Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Raptor Pharmaceuticals Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Raptor Pharmaceuticals Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Raptor Pharmaceuticals Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Raptor Pharmaceuticals Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Raptor Pharmaceuticals Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Raptor Pharmaceuticals Corp. and identify potential opportunities in those areas. SHOW LESS READ MORE >
List of Tables
List of Figures
Raptor Pharmaceuticals Corp. Snapshot
Raptor Pharmaceuticals Corp. Overview
Raptor Pharmaceuticals Corp. – Research and Development Overview
Key Therapeutic Areas
Raptor Pharmaceuticals Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Raptor Pharmaceuticals Corp. – Pipeline Products Glance
Raptor Pharmaceuticals Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Raptor Pharmaceuticals Corp. – Drug Profiles
Mechanism of Action
Raptor Pharmaceuticals Corp. – Pipeline Analysis
Raptor Pharmaceuticals Corp. – Pipeline Products by Therapeutic Class
Raptor Pharmaceuticals Corp. - Pipeline Products By Target
Raptor Pharmaceuticals Corp. – Pipeline Products by Molecule Type
Raptor Pharmaceuticals Corp. – Recent Pipeline Updates
Raptor Pharmaceuticals Corp. – Locations And Subsidiaries
Other Locations & Subsidiaries
Sep 29, 2009: TorreyPines Therapeutics, Inc. Acquired By Raptor Pharmaceuticals Corp.,
Apr 29, 2009: Raptor Pharmaceuticals Receives Notices Of Allowance For Two NeuroTrans Patent Applications
Jun 28, 2010: Raptor Initiates Pivotal Phase III Study Of DR Cysteamine For Treatment Of Cystinosis
Nov 26, 2009: Raptor Pharmaceutical Corp. Announces Positive Data On NGX426 In The Potential Treatment Of Neuropathic Pain
Jul 25, 2011: Raptor Pharmaceutical Meets Primary Endpoint In Phase III Clinical Trial Of Delayed Release Cysteamine For Nephropathic Cystinosis
Jan 24, 2011: Raptor Completes Enrollment In Phase III Clinical Trial Of DR Cysteamine To Treat Nephropathic Cystinosis
Nov 23, 2009: Raptor Pharmaceutical Completes DR Cysteamine Phase IIb Clinical Trial In Cystinosis
Nov 23, 2009: Raptor Pharmaceutical Corp. Announces Positive Data On NGX426 In the Potential Treatment Of Neuropathic Pain
Oct 23, 2007: Tezampanel Meets Primary Endpoint In Phase IIb Clinical Trial In Acute Migraine Headache
Jun 23, 2008: Raptor Pharmaceuticals Corp. Announces Presentation At 5th International Cystinosis Conference 2008
Apr 21, 2008: Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study For Convivia
Jun 15, 2010: Raptor Receives Orphan Medicinal Product Designation For DR Cysteamine From EMA
Feb 15, 2011: Raptor To Enroll Five Additional Patients In Phase III Clinical Trial Of DR Cysteamine For Treatment Of Nephropathic Cystinosis
Sep 13, 2007: Raptor Pharmaceuticals Provides Update Of HepTide
Sep 13, 2007: Raptor Pharmaceuticals Provides Update Of WntTide
Nov 11, 2008: Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results For Convivia Program
Jan 11, 2010: Raptor Pharmaceutical Announces Publication Of Results From Phase IIa Trial Of DR Cysteamine For The Treatment Of Cystinosis
Feb 10, 2010: Raptor To Present DR Cysteamine Data At Lysosomal Disease Network's 2010 WORLD Symposium
Nov 08, 2010: Raptor Pharmaceutical Commences Phase II Clinical Trial Of DR Cysteamine For Treatment Of Huntington's Disease
Nov 06, 2009: Raptor Pharmaceutical Corporation Presents Data For NGX426, A Novel, Non-Opioid Oral Analgesic, At Neuropathic Pain Conference
Nov 06, 2008: Raptor Pharmaceuticals Supports NeuroTrans Platform With Japanese Patent
Jun 06, 2011: Raptor Pharmaceutical Provides Update On Phase III Clinical Trial Of DR Cysteamine For Potential Treatment Of Nephropathic Cystinosis
Mar 04, 2010: Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide in Treatment of Triple-Negative Breast Cancer
Dec 03, 2008: TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint In A Phase II Clinical Trial In Patients With Xerostomia
May 03, 2010: Raptor Announces Positive Phase IIa Results From Non-Alcoholic Steatohepatitis Study
Jun 01, 2009: Raptor Pharmaceuticals Doses First Patient In Phase IIb Clinical Trial Of DR Cysteamine For Cystinosis
Financial Deals Landscape
Raptor Pharmaceuticals Corp., Deals Summary
Raptor Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deal Details
Raptor Pharmaceuticals Acquires ALDH2 From Conviva
Raptor Pharmaceutical Enters Into Research Collaboration With Stanford University
Raptor Pharmaceuticals Merges With TorreyPines Therapeutics
Highland Clan Merges With Raptor Pharmaceutical
Raptor Pharmaceuticals Enters Into Licensing Agreement With Uni Pharma
Raptor Pharmaceuticals Enters Into Licensing Agreement With Weizmann Institute And Niigata University
Raptor Pharmaceuticals Enters Into An Agreement With Roche
Raptor Pharmaceuticals Enters Into Licensing Agreement With University of California
Raptor Pharmaceuticals Enters Into Licensing Agreement With Washington University
Raptor Pharmaceuticals Completes Public Offering Of Common Stock For $46 Million
Raptor Pharmaceuticals Completes Private Placement For $15 Million
Raptor Pharmaceuticals Completes Private Placement Of $7.5 Million
Raptor Pharmaceuticals Completes Private Placement Of $2.62 Million
Raptor Pharmaceutical Completes Private Placement Of Units For $2.4 Million
Raptor Pharmaceuticals Completes Private Placement Of $10 Million
CalciMedica Acquires Assets From TorreyPines Therapeutics
Bennu Pharmaceuticals Acquires Encode Pharmaceuticals
Expert Panel Validation